• vcard
  • Education
    • Ph.D., Stanford University, 2019, Chemistry
    • B.A., with honors, Grinnell College, 2012, Chemistry
  • Bar Jurisdictions
    • Admitted to practice before the United States Patent and Trademark Office, 2020
Dr. Charles Adelson is a registered patent agent in Polsinelli’s Biotechnology and Life Sciences Patent Prosecution group, where he advises clients on patent portfolio and prosecution strategies as well as freedom-to-operate, invalidity, and noninfringement analyses. Charles’ practice focuses on patent prosecution spanning life sciences, chemical, and diagnostic technologies, including biologic and small molecule therapeutics, antibody-drug conjugates biomolecule and organism engineering, transfection methods, novel polysaccharides, and biological assays. 

During his doctoral studies, Charles correlated enzyme structure and function in redox-active biological sites to guide protein and synthetic catalyst design and to elucidate disease-mutation relationships. His research involved spectroscopic, magnetic, and biological characterization techniques, as well as quantum mechanical theory formulation for protein-metal ion covalency quantitation. During his Ph.D., Charles also prospected a CO2 mediation technology in the Stanford Climate Ventures startup incubator.
  • Represented antibody therapeutics company in $250 million financing.
  • Represented proteomics company through product launch.
  • Represented ophthalmic pharmaceutical company during abbreviated new drug application (ANDA).
  • Represented biopharmaceutical company in $177 million IPO